Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.

Manmeet Ahluwalia; Hao Xie; Saurabh Dahiya; Nooshin Hashemi-Sadraei; David Schiff; Paul G. Fisher; Marc C. Chamberlain; Susan Pannullo; Herbert B. Newton; Cathy Brewer; Laura Wood; Richard Prayson; Paul Elson; David Marc Peereboom

doi:10.1007/S11060-014-1684-Y

Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.

Manmeet Ahluwalia, Hao Xie, Saurabh Dahiya, Nooshin Hashemi-Sadraei, David Schiff, Paul G. Fisher, Marc C. Chamberlain, Susan Pannullo, Herbert B. Newton, Cathy Brewer, Laura Wood, Richard Prayson, Paul Elson, David Marc Peereboom

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
Volume	122
DOIs	https://doi.org/10.1007/S11060-014-1684-Y
State	Published - Mar 1 2015

Disciplines

Medicine and Health Sciences
Oncology
Surgery
Internal Medicine

Access to Document

10.1007/S11060-014-1684-YLicense: Unspecified

Cite this

Ahluwalia, M., Xie, H., Dahiya, S., Hashemi-Sadraei, N., Schiff, D., Fisher, P. G., Chamberlain, M. C., Pannullo, S., Newton, H. B., Brewer, C., Wood, L., Prayson, R., Elson, P., & Peereboom, D. M. (2015). Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. Journal of neuro-oncology, 122. https://doi.org/10.1007/S11060-014-1684-Y

Ahluwalia, M, Xie, H, Dahiya, S, Hashemi-Sadraei, N, Schiff, D, Fisher, PG, Chamberlain, MC, Pannullo, S, Newton, HB, Brewer, C, Wood, L, Prayson, R, Elson, P & Peereboom, DM 2015, 'Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.', Journal of neuro-oncology, vol. 122. https://doi.org/10.1007/S11060-014-1684-Y

@article{4401cd57e61f4751b9e29506c540095b,

title = "Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.",

author = "Manmeet Ahluwalia and Hao Xie and Saurabh Dahiya and Nooshin Hashemi-Sadraei and David Schiff and Fisher, \{Paul G.\} and Chamberlain, \{Marc C.\} and Susan Pannullo and Newton, \{Herbert B.\} and Cathy Brewer and Laura Wood and Richard Prayson and Paul Elson and Peereboom, \{David Marc\}",

note = "Standard initial therapy for patients with pure and mixed anaplastic oligodendrogliomas (AO/MAO) includes chemotherapy and radiation therapy. Anaplastic oligodendrogliomas with 1p/19q co-deletion are more responsive to chemotherapy. There is concern for potential long-term CNS toxicity of radiation. Hence an approach using chemotherapy initially and reserving radiation for progressive disease is attractive.",

year = "2015",

month = mar,

day = "1",

doi = "10.1007/S11060-014-1684-Y",

language = "American English",

volume = "122",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.

AU - Ahluwalia, Manmeet

AU - Xie, Hao

AU - Dahiya, Saurabh

AU - Hashemi-Sadraei, Nooshin

AU - Schiff, David

AU - Fisher, Paul G.

AU - Chamberlain, Marc C.

AU - Pannullo, Susan

AU - Newton, Herbert B.

AU - Brewer, Cathy

AU - Wood, Laura

AU - Prayson, Richard

AU - Elson, Paul

AU - Peereboom, David Marc

N1 - Standard initial therapy for patients with pure and mixed anaplastic oligodendrogliomas (AO/MAO) includes chemotherapy and radiation therapy. Anaplastic oligodendrogliomas with 1p/19q co-deletion are more responsive to chemotherapy. There is concern for potential long-term CNS toxicity of radiation. Hence an approach using chemotherapy initially and reserving radiation for progressive disease is attractive.

PY - 2015/3/1

Y1 - 2015/3/1

UR - https://link.springer.com/article/10.1007/s11060-014-1684-y

U2 - 10.1007/S11060-014-1684-Y

DO - 10.1007/S11060-014-1684-Y

M3 - Article

VL - 122

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.

Disciplines

Access to Document

Other files and links

Cite this